Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Viral attachment to host cell" describes the initial step in viral infection where specific proteins or glycans on the virus bind to particular receptors, adhesion molecules, or glycans on the host cell surface[1][2][3][5]. This process mediates host specificity, cell tropism, and is a prerequisite for viral entry, which can proceed via direct membrane fusion, endocytosis, or other mechanisms depending on the virus[3][5]. Attachment is mediated by viral proteins (such as the spike protein in SARS-CoV-2 or the glycoprotein in HIV) that recognize and bind host molecules including sialylated glycans, integrins, immunoglobulin superfamily members, and others[2][3][4]. Therapies targeting viral attachment aim to prevent the virus from binding to its host entry receptor, thus blocking infection at its earliest stage[3][4][5].
Blockade of virus binding to host receptor (antibodies or receptor mimics); Inhibition of membrane fusion (fusion inhibitors); Competitive inhibition of receptor binding (decoy receptors or small molecules)
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Viral attachment to host cell.